Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 626 - 650 of 1992 in total
Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin. In gout patients treated with pegloticase, the conversion of...
Approved
Investigational
Matched Description: … of pegloticase and methotrexate. ... [A249980] However, cases of anaphylaxis and infusion reactions have been reported in patients treated ... Therefore therapeutic drug levels can be maintained with infrequent and relatively low pegloticase doses …
Matched Categories: … Enzymes and Coenzymes …
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved...
Approved
Investigational
Matched Description: … It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used ... [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the …
Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. It is also produced by Malassezia furfur, also known as Pityrosporum ovale, which is a species of fungus that is normally found on human skin. Azelaic acid is effective against a number of skin conditions, such...
Approved
Matched Description: … furfur_, also known as _Pityrosporum ovale_, which is a species of fungus that is normally found on human ... Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. ... It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear …
Matched Categories: … Skin and Mucous Membrane Agents …
A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and...
Approved
Investigational
Matched Description: … It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin ... , and retina thus plays an important role in their development and function. ... A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement …
Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause...
Approved
Investigational
Withdrawn
Matched Description: … the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and ... the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and ... re-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and
Matched Categories: … Alimentary Tract and Metabolism …
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human...
Approved
Matched Description: … [L40714] Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from ... Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor ( ... [L40719] It has a number of therapeutic uses, including the management and prevention of infections and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been...
Approved
Investigational
Matched Description: … metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and
Clove oil is obtained by extraction from the dried flower buds of the clove plant. Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities. The antioxidant and antimicrobial...
Approved
Nutraceutical
Matched Description: … The antioxidant and antimicrobial activity of clove is higher than that of many fruits, vegetables, and ... _gallic acid_ and has great potential for pharmaceutical, cosmetic, food and agricultural applications ... plant represents one of the richest source of phenolic compounds such as _eugenol_, _eugenol acetate_ and
Chromium is a transition element with the chemical symbol Cr and atomic number 24 that belongs to Group 6 of the periodic table. It is used in various chemical, industrial and manufacturing applications such as wood preservation and metallurgy. The uses of chromium compounds depend on the valency of chromium,...
Approved
Matched Description: … be human carcinogens [L1982]. ... It is used in various chemical, industrial and manufacturing applications such as wood preservation and ... non-pregnant female are 35 μg and 25 μg, respectively [L1986]. …
Matched Mixtures name: … Chromium and Vanadium (combo) ... Vitamin and Mineral Drink Mix ... Prenatal Vitamin and Mineral Supplement …
Matched Categories: … Diet, Food, and Nutrition …
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF ... pharmacokinetic profile and conditions of use. ... than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, spermidine and spermine. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985...
Approved
Investigational
Matched Description: … It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. ... Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective ... TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925 …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be...
Approved
Matched Description: … receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and ... A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and ... [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …
Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys. Several preparations of cysteamine exist...
Approved
Investigational
Matched Description: … in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and ... preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and ... L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism …
Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body....
Approved
Matched Description: … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and ... Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. ... , but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and
Matched Categories: … Eslicarbazepine and prodrugs …
Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging.
Approved
Matched Description: … for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and
Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.[A253642,A253647] It is similar to other GnRH receptor antagonists like cetrorelix, relugolix, and elagolix. Uterine fibroids occur in >70% of women of reproductive...
Approved
Matched Description: … , and reproductive dysfunction. ... [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and ... Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins …
Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of Ketamine. Ketamine...
Approved
Investigational
Matched Description: … Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness ... The intranasal route of administration for this drug allows for easy administration and a fast onset ... disorder who have not experienced an improvement in symptoms despite treatment with various medications and
Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Approved
Investigational
Matched Description: … [L50642] As CXCR4 mutations have also been implicated in human immunodeficiency virus (HIV), Waldenstrom ... approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and ... syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory ... in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized...
Approved
Matched Description: … Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human ... exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and ... activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and
Matched Categories: … darunavir and cobicistat ... atazanavir and cobicistat ... Metabolic Side Effects of Drugs and Substances ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat ... emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat …
Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
Approved
Investigational
Matched Description: … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug ... thus poorer overall survival and higher risk of relapse. ... anthracycline induction and standard cytarabine consolidation, followed by a maintenance monotherapy …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing...
Approved
Matched Description: … and pharmacologically related to clopidogrel and ticlopidine. ... Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada ... As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. …
Matched Categories: … Blood and Blood Forming Organs …
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Approved
Matched Description: … , bladder, and kidneys. ... It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges …
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Approved
Matched Description: … A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee...
Approved
Investigational
Matched Description: … The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization ... Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors ... Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines …
Displaying drugs 626 - 650 of 1992 in total